首页> 外文期刊>European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology >Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases.
【24h】

Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases.

机译:动脉内输注5-氟尿嘧啶加粒细胞巨噬细胞集落刺激因子(GM-CSF)并用美法仑进行化学栓塞治疗散播性结直肠肝转移。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: We compared two prospective trials of intra-arterial cytokine/chemotherapeutic infusion plus chemoembolization in the treatment of inoperable colorectal liver metastases. MATERIALS AND METHODS: One hundred and three patients with disseminated inoperable colorectal liver metastases received intra-arterial chemotherapy with 5-FU and granulocyte-macrophage colony-stimulating factor (GM-CSF) plus chemoembolization via an angiographically positioned hepatic artery catheter. Two different regimens were used in two consecutive studies. Group A: short-term i.a. infusion of 550 mg/m(2)5-FU (days 1-4) plus 80 microg/m(2)GM-CSF (day 1+2) combined with chemoembolization with 25 mg/m(2)melphalan plus Lipiodol and Gelfoam (day 5). Group B: continuous circadian intra-arterially administered 1400 mg/m(2)5-FU infusion plus 60 mg/m(2)i.v. leucovorin and 80 microg/m(2)GM-CSF (day 1+2) combined with chemoembolization with 25 mg/m(2)melphalan plus Lipiodol and Gelfoam (day 3). RESULTS: One hundred and three patients (62 male/41 female) with a median age of 59.9 and a median Karnofsky index of 88.5 were treated with 447 cycles of immuno-chemoembolization (group A 299, group B 148 cycles). Fifty-seven percent of these patients had received prior systemic chemotherapy. Side-effects were seen in all patients, mainly upper abdominal pain lasting 1-4 days and grade 1 or 2 vomiting. Systemic side-effects were mild and transient with a very low rate of leukopenia. Using World Health Organization response criteria, the following responses could be demonstrated: group A: CR 2.7%, PR 32.4%, MR 21.6%, SD 12.7%, NR 16.2%; group B: CR 1.0%, PR 42.4%, MR 24.2%, SD 18.2%, NR 12.1%. Time to progression was 7 as compared to 8 months. Median survival was 17 months in group A, whereas it has not been reached after 28 months (P=0.0095) in group B. There was no statistically significant difference between chemo-naive patients and patients who had received prior systemic therapy. CONCLUSION: Immuno-chemoembolization combined with 2-day circadian administration of 5-FU is an effective tool in the treatment of disseminated colorectal liver metastases. This regimen is also effective as second-line treatment.
机译:目的:我们比较了动脉内细胞因子/化疗输注加化学栓塞治疗无法手术的结直肠肝转移的两项前瞻性试验。材料与方法:一百零三名弥散性无法手术的大肠肝转移患者接受了5-FU和粒细胞巨噬细胞集落刺激因子(GM-CSF)的动脉内化疗,并通过血管造影定位的肝动脉导管进行了化疗栓塞。在两个连续的研究中使用了两种不同的方案。 A组:短期550 mg / m(2)5-FU(第1-4天)加80 microg / m(2)GM-CSF(第1 + 2天)输注与25 mg / m(2)美法仑加Lipiodol和Gelfoam(第5天)。 B组:连续进行昼夜节律动脉内给药1400 mg / m(2)5-FU,加60 mg / m(2)i.v。亚叶酸和80 microg / m(2)GM-CSF(第1天和第2天)结合化学栓塞用25 mg / m(2)美法仑加Lipiodol和Gelfoam(第3天)。结果:103例患者(中位年龄为59.9岁,中位卡诺夫斯基指数为88.5)接受了447个免疫化学栓塞治疗(A组299个,B组148个周期)。这些患者中有57%曾经接受过全身化疗。在所有患者中均观察到副作用,主要是持续1-4天的上腹部疼痛和1或2级呕吐。全身的副作用是轻度的和短暂的,白细胞减少症的发生率非常低。使用世界卫生组织的回应标准,可以证明以下回应:A组:CR 2.7%,PR 32.4%,MR 21.6%,SD 12.7%,NR 16.2%; B组:CR 1.0%,PR 42.4%,MR 24.2%,SD 18.2%,NR 12.1%。进展时间为7个月,而8个月则为7个月。 A组的中位生存期为17个月,而B组的28个月后仍未达到中位生存期(P = 0.0095)。单纯化疗患者与先前接受过全身治疗的患者之间无统计学差异。结论:免疫化学栓塞联合昼夜节律5-FU治疗是治疗散播性大肠肝转移的有效方法。该方案作为二线治疗也是有效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号